The Top 15 Best-Selling Drugs of 2016

ต้อนรับเข้าสู่ Q4 2016 วันนี้ก็เลยเอายอดขายยาปี 2016 ในภาพรวมทั้งโลกนะครับ
ส่วนใหญ่ยาที่ขายดี จะเป็นกลุ่มยารักษาโรคมะเร็ง และ ยารักษาโรคเรื้อรัง
ส่วนจะเป็นตัวไหนบ้างไปดูกันครับ





15. Advair /Seretide (fluticasone and salmeterol)
   
     GlaxoSmithKline

     2016 sales: $4.325 billion (£3.485 billion)

     2015 sales: $4.568 billion (£3.681 billion)

      % Change: (5.3%)

14. Neulasta / Peglasta (pegfilgrastim) and Neupogen / Gran (filgrastim)

      Amgen and Kyowa Hakko Kirin

      2016 sales: $4.701 billion ($4.648 billion Amgen + $0.053 billion [¥5.9 billion]

     Kyowa Hakko Kirin

     2015 sales: $4.752 billion ($4.715 billion Amgen + $0.037 billion [¥4.1 billion]

     Kyowa Hakko Kirin

     % Change: (1.1%)

13. Lyrica® (pregabalin)

      Pfizer

     2016 sales: $4.966 billion

     2015 sales: $4.838 billion

     % Change: 2.6%

12. Eylea (aflibercept)

      Bayer and Regeneron Pharmaceuticals

      2016 sales: $5.045 billion ($1.722 billion [€1.625 billion Bayer + $3.323 billion Regeneron)

      2015 sales: $3.977 billion ($1.301 billion [€1.228 billion Bayer + $2.676 billion Regeneron)

      % Change: 26.9%

11. Xarelto™ (rivaroxaban)

      Bayer and Johnson & Johnson

      2016 sales: $5.390 billion ($3.102 billion [€2.928 billion] Bayer + $2.288 billion J&J)

      2015 sales: $4.254 billion ($2.386 billion [€2.252 billion] Bayer + $1.868 billion J&J)

      % Change: 26.7%

10. Prevnar 13® / Prevenar 13® (Pneumococcal 13-valent Conjugate Vaccine
   
      [Diphtheria CRM197 Protein])

      Pfizer

     2016 sales: $5.718 billion

     2015 sales: $6.245 billion

     % Change: (8.4%)

9. Lantus® (insulin glargine)

    Sanofi

    2016 sales: $6.054 billion (€5.714 billion)

    2015 sales: $6.770 billion (€6.390 billion)

    % Change: (10.6%)

8. Herceptin® (trastuzumab)

    Roche (Genentech)

    2016 sales: $6.751 billion (CHF 6.782 billion)

    2015 sales: $6.509 billion (CHF 6.538 billion)

    % Change: 3.7%

7. Avastin® (bevacizumab)

    Roche (Genentech)

    2016 sales: $6.752 billion (CHF 6.783 billion)

    2015 sales: $6.654 billion (CHF 6.684 billion)

    % Change: 1.5%

6. Revlimid® (lenalidomide)

    Celgene

    2016 sales: $6.974 billion

    2015 sales: $5.801 billion

    % Change: 20.2%

5. Remicade® (infliximab)

    Johnson & Johnson and Merck

   2016 sales: $7.829 billion ($6.561 billion J&J + $1.268 billion Merck)

   2015 sales: $8.760 billion ($6.966 billion J&J + $1.794 billion Merck)

   % Change: (10.6%)

4. Rituxan® (rituximab, MabThera)

    Roche (Genentech) and Biogen

    2016 sales: $8.583 billion ($7.268 billion [CHF 7.300 billion] Roche + $1.315 billion Biogen)

    2015 sales: $8.354 billion ($7.015 billion [CHF 7.045 billion] Roche + $1.339 billion Biogen)

    % Change: 2.7%

3. Enbrel® (etanercept)

    Amgen and Pfizer

    2016 sales: $8.874 billion ($5.965 billion Amgen + $2.909 billion Pfizer)

    2015 sales: $8.697 billion ($5.364 billion Amgen + $3.333 billion Pfizer)

    % Change: 2.0%

2. Harvoni® (ledipasvir 90 mg/sofosbuvir 400 mg)

    Gilead Sciences

    2016 sales: $9.081 billion

    2015 sales: $13.864 billion

    % Change: (34.5%)

1. Humira® (adalimumab)

    AbbVie

    2016 sales: $16.078 billion

    2015 sales: $14.012 billion

    % Change: 14.7%

Credit : www.genengnews.com

ภก.ภูริทัต ว่องพุฒิพงศ์